Upleganan clinical trials
Also written SPR206.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses upleganan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SPR206
- 3
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses upleganan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal FunctionCompletedPhase 1Spero TherapeuticsNCT04865393Written as SPR206
- Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy VolunteersCompletedPhase 1Spero TherapeuticsNCT04868292Written as SPR206
- A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy VolunteersCompletedPhase 1Spero TherapeuticsNCT03792308Written as SPR206
Codes
What other systems call upleganan · ClinicalTrials.gg INT016784
- UNII (FDA) HL5KS3G9R2UPLEGANANOne source FDA
- NCI Thesaurus C199124UplegananOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HL5KS3G9R2 | UPLEGANAN | One source FDA |
| NCI Thesaurus | C199124 | Upleganan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.